Menu
Search
|

Menu

Close
X

NewLink Genetics Corp NLNK.OQ (NASDAQ Stock Exchange Global Market)

4.55 USD
-0.16 (-3.40%)
As of Jul 18
chart
Previous Close 4.71
Open 4.69
Volume 74,897
3m Avg Volume 220,707
Today’s High 4.74
Today’s Low 4.53
52 Week High 19.30
52 Week Low 3.76
Shares Outstanding (mil) 37.17
Market Capitalization (mil) 175.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
29
FY16
36
FY15
69
EPS (USD)
FY18
-0.493
FY17
-2.352
FY16
-2.942
FY15
-1.444
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
4.88
8.00
Price to Book (MRQ)
vs sector
1.27
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.15
17.41
LT Debt to Equity (MRQ)
vs sector
0.07
13.26
Return on Investment (TTM)
vs sector
-52.12
13.14
Return on Equity (TTM)
vs sector
-55.08
15.15

EXECUTIVE LEADERSHIP

Charles Link
Chairman of the Board, Chief Executive Officer, Chief Scientific Officer, Since 2009
Salary: $573,200.00
Bonus: $1,354,860.00
Nicholas Vahanian
President, Since 2017
Salary: $453,600.00
Bonus: $887,667.00
John Henneman
Chief Financial Officer, Secretary, Since 2014
Salary: $90,000.00
Bonus: $2,990,970.00
Eugene Kennedy
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Brian Wiley
Chief Commercial Officer, Since 2016
Salary: $262,500.00
Bonus: $338,917.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2503 S Loop Dr Ste 5100
AMES   IA   50010-8641

Phone: +1515.2965555

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

SPONSORED STORIES